ClinicalTrials.gg
Status unknownNCT03398551Updated Jan 12, 2018

Machine Learning From Fetal Flow Waveforms to Predict Adverse Perinatal Outcomes

An observational study in Perinatal Mortality and Neonatal Morbidities, sponsored by Aga Khan University. Status unknown. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-12.

Sponsored by Aga Khan University · Observational

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
525
Sex
Female
01

Study summary

The aim of this study is to get a proof of concept for using a computational model of fetal haemodynamics, combined with machine learning based on Doppler patterns of the fetal cardiovascular, cerebral and placental flows, to identify those at increased risk of adverse perinatal outcomes such as stillbirth, perinatal mortality and other neonatal morbidities.

We will also compare the sensitivity and specificity of UmbiFlow device with the machine learning model in predicting adverse perinatal outcomes

Read the detailed description

Pakistan is one of the countries where stillbirth rate (43/1000 total births) and neonatal mortality rate (55/1000 live births) are among the highest in the world. The figures for perinatal mortality remained unchanged between Pakistan Demographic and Health Survey (PDHS) 1990-91 and PDHS 2012-13. It is hence important to evaluate new techniques to identify high-risk pregnant women who can then subsequently receive personalized care to improve perinatal outcomes. Fetal blood flow waveforms assessed via Doppler ultrasound to indicate wellbeing of the fetus have been in practice for nearly four decades. Abnormal blood flow patterns in the fetal circulation detected by Doppler ultrasound may indicate poor fetal prognosis. These tracings will then be incorporated in a computational model and combined with machine learning, will be used to predict adverse perinatal outcomes.

This will be a prospective one group cohort study for a period of twelve months which will be based in Ibrahim Hyderi, a peri-urban settlement of approximately 70,000 on the south east of Karachi. The sample size for this study has been calculated based on the outcomes of the pregnancy and was estimated to be 525 pregnant women.

Recruitment - Household surveillance will be done by community health workers (CHWs) in the catchment area in a sequential manner to identify pregnant women. Eligible women between 22-34 weeks of gestation on last menstrual period (LMP) will then be explained regarding the purpose of the study and invited for an ultrasound scan.

First and enrollment visit - The first visit window for the ultrasound scan will be between 22-26 weeks of gestation. This window is selected because pregnancies at risk may be better identified and also visualization of fetal cardiac flow is possible. Based on the rigorous surveillance, we anticipate that most women will be in this window. The following information will be collected:

  • Socio-demographic information
  • Medical history, including exposure to tobacco, gravidity, parity, past obstetric history (including number of miscarriages, stillbirths or neonatal deaths) and comorbid conditions (pre-eclampsia, diabetes mellitus)
  • Maternal anthropometry (height, weight and mid-upper arm circumference)
  • Maternal blood pressure
  • Hemoglobin of the mother
  • Symphysiofundal height will be measured
  • Standard obstetric Doppler evaluation including the four primary ultrasound measures of fetal growth-head circumference, biparietal diameter, abdominal circumference, and femur length is routinely performed for all pregnant women presenting at the center. These parameters will be used to estimate fetal weight (automatically calculated by the machine).
  • Focused Fetal Doppler Echocardiography - These would include transabdominal measurements of the Doppler velocity of the umbilical artery, the middle cerebral artery (MCA), ductus arteriosus, fetal aortic isthmus (AoI) and left and right ventricular outflow tracts
  • UmbiFlow - Umbilical artery continuous wave Doppler image will also be obtained on these women. The device will generate graphs for the flow pattern and calculate the resistance index for the flow.

Second visit - The second visit window of ultrasound scan will be between 30-34 weeks of gestation. This will be applicable for all women who have had their first scan during 22-26 weeks of gestation as well as newly enrolled women during 30-34 weeks of gestational age. Cardiotocography (CTG) will be performed for all recruited women during the second visit followed by the Doppler examination. The same procedures as described in the first visit will be done.

Follow up - We will obtain contact information (phone number) from all enrolled women. A trained research midwife will be responsible for making phone calls, as well as performing household visits at pre-specified intervals for immediate and early identification of the pregnancy outcome. A team of CHWs will perform home visits to the baby at post-natal day 1 and 6 and questions related to delayed cry, neonatal sepsis and hospital course (if any) will be collected and the weight and length of the baby will be recorded.

Verbal autopsy - The VA team will visit the family after the grieving period (at least 14 days after the death). VA will be performed using a structured tool (http://www.who.int/healthinfo/statistics/WHO_VA_2012_RC1_Instrument.pdf ).

02

Conditions studied

  • Perinatal Mortality
  • Neonatal Morbidities

Browse trials for

Keywords

  • pregnancy
  • machine learning
  • fetal Doppler echocardiography
03

In context

Perinatal Death

120 studies on the registry are indexed under Perinatal Death; 25 are open to participants now.

This study's planned enrollment of 525 is close to the median of 525 across 33 observational studies indexed under Perinatal Death.

Browse Perinatal Death studies →

Lead sponsor

Aga Khan University is the lead sponsor of 294 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Pregnant women between 22-34 weeks who reside in Ibrahim Hyderi Goth which is a peri-urban settlement of approximately 70,000 on the south east of Karachi. It is one of the seven union councils in Bin Qasim town which has a population of one million.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant woman coming to the ultrasound clinic between 22-34 weeks of gestation.
  • Written
  • Resident of the study area

Exclusion criteria

Exclusion Criteria:

  • Multiple gestation
  • Known congenital anomaly in the fetus or newborn
  • Refusal for the ultrasound
  • Poor echocardiographic images for Doppler acquisition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
525 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Stillbirth

    Baby born with no signs of life at or after 28 weeks of gestation

    Time frame: At birth

  2. Early neonatal mortality

    Death of a baby within the first 7 days of life

    Time frame: Within the first 7 days of life

Secondary outcomes

  1. IUGR

    Fetal weight that is below the 10th percentile for gestational age as determined through an ultrasound

    Time frame: At birth

  2. Prematurity

    Birth of a fetus at \< 37 weeks of gestation

    Time frame: At birth

  3. Birth asphyxia

    Delayed cry after at least 1 minute of life

    Time frame: At birth

  4. Neonatal sepsis

    Any 1 of the following danger signs: fever \> 38 of \< 35.5 C, convulsions, lethargy, poor feeding, chest in drawing and tachypnea (respiratory rate \> 60/min)

    Time frame: Within the first 7 days of life

  5. Low Birth Weight

    Birth weight \< 2.5 kg

    Time frame: At birth

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2018; primary completion for Sep 2018, 7 months later.

Of 17 observational studies under Perinatal Death, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 119. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2018
First posted
Jan 12, 2018
StartEst.
Feb 2018
Primary completionEst.
Sep 2018
CompletionEst.
Dec 2018
Last update
Jan 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03398551
Collaborators
Universitat Pompeu Fabra
Responsible party
Zahra Hoodbhoy (Dr Zahra Hoodbhoy, Aga Khan University) — Principal investigator
First posted
Jan 12, 2018
Start date
Feb 2018 (estimated)
Primary completion
Sep 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Jan 12, 2018

Study contacts

Zahra Hoodbhoy
Contact
zahra.hoodbhoy@aku.edu
92-21-34930051 ext. 4126
Babar Hasan
Contact
babar.hasan@aku.edu
92-21-34930051 ext. 4364

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion